Presenter Anna Daily Ph.D.-Senior Scientist March 9, 2012 Breast Health Providers Conference.

Presenter Anna Daily Ph.D.-Senior Scientist

March 9, 2012Breast Health Providers Conference

Why A New Approach to Breast Cancer Screening?

Of women age 40 and over with insurance coverage only 50% participate in yearly screenings.

Why women don’t participate: Dense Breast Tissue Lack of Facility Access Some find procedure painful Cost prohibitive for uninsured False Positive rate of 5% per exam= 50%

over per patient lifetime

Ascendant Diagnostics is Developing:

An inexpensive, highly accurate test that can diagnose cancer at earlier stages is highly sought after

A Low Cost

Non-Invasive

Screening Method for Breast Cancer

Detects proteins present in tear samples

Based on technology licensed from UAMS

Why Tears?Easy and Quick to CollectPain FreeNon-invasiveContain Protein in High ConcentrationsEasy to Prep for Test

Cancer

No Cancer

SELDI TOF MS

Bioinformatic analysisDiagnostic fingerprintNew targets

Cancer

No Cancer

SELDI TOF MS

Bioinformatic analysisDiagnostic fingerprintNew targets

Analyze Tears byMass Spectrometry

Collect Tear Sample Look for Differences

Mass Spectrometry

Private Industry Quest LabCorp PeaceHealth Labs

Drug TestingMonitoring Pain MedicationMonitor metabolic disorders

Separates samples based on Size4045.798

14691.861

16421.046

17439.8153122.430

8211.19511719.514

13899.559

0.0

0.5

1.0

1.5

2.0

2.5

4x10

Inte

ns.

[a.u

.]

2000 4000 6000 8000 10000 12000 14000 16000 18000 20000m/z

Increasing sizeIn

tensi

tyB

igger

peak=

more

pro

tein

Genomics vs. Proteomics

DNA Sequences Protein Structure and Function

Predictive of RiskNot Diagnostic Diagnostic

Imaging is the Gold Standard

TechniqueIonizing Radiatio

n

Breast Compressio

n

False Negative

Rate

False Positive

Rate

Mammography Yes YES 10-30% Up to 75%

Ultrasound No No >30% Up to 65%

PET Yes No 15-25% 25 to 75%

MRI No No 1-15% 25 to 75%

Tear Testing80% Sensitive75% Specific

90% Sensitive90% Specific

$75.00 per test vs. $200 for mammogram

Regulatory Pathway

CLIA: Clinical Laboratory Improvements Amendment

Timeline

2011 2012 2013 2014 2015

Licensed Technology;

Business Case;

Established Strategic

Partnerships

Protein Biomarker

Identification; 2 cohorts of 300 patients;

establish more

partnerships; develop CLIA

protocol

Clinical Validation; Marketing and Sales

Team Build up

Contract Development

of POC Lab on a Chip

and Contract Development of Reagents;

Sales and Mktg.

Other Cancer

biomarkers; lines

between treatment

and level of protein

Collaborations

• The Breast Center – established February 2012– 300 tear samples over the next 2 years

• Winthrop P. Rockefeller Cancer Institute Women’s clinic (UAMS)– In Progress– 300 tear samples over the next 2 years

• Peace Health Labs– Established August 2011– Aid and in development and testing of CLIA lab protocol

• University of Arkansas Statewide Mass Spectrometry Facility– established February 2011– Acess to mass spectrometry instrumentation– Collabroations on Grant applications– Aid in development of CLIA based protocol

Management Team

Scientific Advisory Board

Contact Information Omid Moghadam CEO 479-571-2592 [email protected]

Anna Daily Ph.D. Scientist [email protected]